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Abstract This article answers two questions concerning the liability aspects of the use of
“may contain” labelling on food packages, such as “This product may contain traces of
nuts.” This type of voluntary labelling refers to the unintentional presence of an allergenic
foodstuff, the inclusion of which can occur during the production process. Firstly, it is
probable that courts consider a food product without a “may contain” warning defective
under the Directive, even though this can create unintended consequences. This question is
approached in terms of a defect both in design and in warning, since food manufacturers are
able to reduce the risk by means of redesigning the production process or by providing a
warning. With regard to the second liability question concerning the adequacy of “may
contain” warnings, it is not likely that courts will consider the product warning defective in
view of the difficulty of providing a better alternative.
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Introduction
After eating a chocolate-chip cookie from a vending machine, a 19-year-old girl who
suffers from a peanut allergy developed symptoms of anaphylactic shock and was
rushed to the emergency room. The list of ingredients on the cookie’s package did not
include peanuts (Sampson 2002). Evidently, the allergic patient fell victim to a trace
amount of hidden peanut. The presence of the hidden allergen may stem from the fact
that the production of chocolate-chip cookies occurs on the same line as peanut cookies,
and the chocolate-chip cookies were manufactured after the production process of peanut
cookies.
This is an illustrative example of how the risk of cross-contamination of allergens can
take place in real life. The term “cross-contamination” or “cross-contact” of allergens refers
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to the unintentional presence of an allergenic foodstuff in the final food product (FSA 2006,
p. 57). Cross-contamination occurs when different products come into contact with each
other: for example, during the production process. It usually concerns only trace amounts of
allergens, but even these can have fatal consequences.
In recent years, food manufacturers have increasingly issued warnings such as “This
product may contain traces of nuts” or “This product is made on a production line that also
handles sesame” on pre-packed food labels. They provide these statements on a voluntary
basis to warn consumers against allergens that are or may be unintentionally present in their
foodstuffs. It has been suggested that manufacturers provide “may contain” labels to protect
themselves against product liability. Product liability under the European Directive requires
that the product is defective, which means that the product has failed to meet the safety
consumers are entitled to expect. From a manufacturer’s point of view, the presence of a
“may contain” statement could preclude a successful claim brought against him by an
allergic consumer who has suffered injuries as a result of the unintentional presence of an
allergen. Interesting in this regard is whether the fear that an allergic victim will succeed in
claiming compensation is in accordance with civil safety standards.
In this article, the liability aspects of the use of labelling allergen cross-contamination will
be examined. Firstly, the question is whether a food product can be deemed as defective in
the event that a warning of the risk of cross-contamination is absent and an allergic consumer
has suffereds injuries as a result of the unintentional presence of an allergen. Secondly, in the
event a “may contain” warning is present on the food label, the liability question arises as to
how manufacturers should warn against the risk of cross-contamination, taking into the
account the information needs and information processing abilities of consumers.1
The structure of the article is as follows: “A Case of Food Allergen Cross-Contamination” starts
with a description of the specific details of the allergen cross-contamination case. The nature and
scope of the Directive are discussed in “Product Liability Under the European Directive.”
Subsequently, the answer to the first question mentioned above is dealt with in “A Design
Defect,” “A Warning Defect,” “Risk Analysis of Courts,” and “A Non-standard Product.” The
second liability question is examined in “The Adequacy of an Allergen Cross-Contamination
Warning.” The closing paragraph provides a summary of the findings of the article.
A Case of Food Allergen Cross-Contamination
The Food Label
The first step of this exercise consists of exploring the details of the allergen cross-
contamination case. The starting point is that the food product contains no statement that
points to the risk of cross-contamination. Furthermore, the appearance of the product itself
does not indicate the presence of an undeclared allergen. Hence, allergy sufferers cannot
conclude from the presentation of the product, mainly its label, that potential danger exists.
Food Safety Regulations
In recent years, the issue of food allergies and cross-contamination has been recognised by
the European Commission and the food industry. However, the declaration of the risk of
1 I do not address the question of whether “may contain” labelling should be the focus of legislative attention
or whether a regulatory approach is superior to a tort law approach in dealing with this issue.
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allergen cross-contamination on pre-packed food labels is not covered by EU measures.
Directive 2003/89/EC only sets out the labelling requirements for allergens that have been
intentionally added to foodstuffs as an ingredient.2 The allergen Directive has been in force
since November 2005 and has introduced a list of 12 common allergens that need to be
labelled.3 These are cereals containing gluten, crustaceans, eggs, fish, peanuts, soybeans,
milk, nuts, celery, mustard, sesame, sulphur dioxide, and sulphites, as well as any product
derived from such allergens. Lupine and molluscs and any product thereof have recently been
added to the list.4 According to the first recital, the aim of allergen labelling is to protect the
health of allergic consumers and in particular to provide those suffering from food allergies or
intolerances with more comprehensive information on the composition of products.
Furthermore, EU provisions stipulating how to deal with the risk of cross-contamination
are absent as well. As a result, food manufacturers have different allergen policies and
disparate criteria for the use of “may contain” labelling. Although there are no specific
provisions on this matter, food safety law does lay down general principles that are
applicable to safety hazards such as allergens. According to the General Food Law, a food
business operator has the primary legal responsibility to ensure food safety, as he is best
placed to devise a secure system for supplying food and ensuring that it is safe.5 Moreover,
article 14 of the General Food Law implies that food manufacturers must take into account
special categories of people who may want to consume the product, such as allergic
sufferers. If they fail to do so, the food may be deemed unsafe and must not be placed on
the market. In addition, European food business operators are obliged to apply Hazard
Analysis and Critical Control Point (HACCP) principles to their safety system according to
Regulation 852/2004 on the hygiene of foodstuffs.6 A food safety system based on HACCP
focuses on identifying hazards, such as allergens, and establishing the critical control points
in the process where food safety hazards could arise. These points must be monitored in
order to reduce or to prevent the hazards in an adequate manner. Allergen cross-
contamination can be managed by these principles, but manufacturers themselves need to
determine the critical points. Most have devised specific guidelines for the handling of
allergens through each stage of the product life cycle (Crevel 2002, p. 943). Voluntary
guidelines have been drawn up by the industry or regulatory agencies to help food
businesses manage and communicate the risk of cross-contamination (FSA 2006). In
addition, scientific research provides accessible information to support producers who want
to tackle allergen problems.
Knowledge of the Risk of Cross-Contamination
Another important aspect that characterizes the present case is the degree of consumers’
knowledge of the risk of cross-contamination. Generally, the risk of cross-contamination
2 Council Directive 2003/89/EC of 10 November 2003 amending Directive 2000/13/EC as regards indication
of the ingredients present in foodstuffs (OJ 2003, L308/15). The general provisions for food labelling are set
out in Council Directive 2000/13/EC of 20 March 2000 on the approximation of the laws of the Member
States relating to the labelling, presentation, and advertising of foodstuffs (OJ 2000, L 109/29).
3 Council Directive 2003/89/EC of 10 November 2003 amending Directive 2000/13/EC as regards indication
of the ingredients present in foodstuffs (OJ 2003, L308/15).
4 Commission Directive 2006/142/EC of 22 December 2006 amending Annex IIIa of Directive 2000/13/EC
of the European Parliament and of the Council listing the ingredients that must under all circumstances
appear on the labelling of foodstuffs (OJ 2007, L368/110).
5 Regulation (EC) 178/2002 (OJ 2002, L31/1), recital 30 and article 17.
6 Regulation(EC) 852/2004 (OJ 2004, L139/1).
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can be viewed as a known threat to food-allergic consumers. Since the risk of cross-
contamination can occur even at home during food preparation or cooking, allergic
consumers must always be vigilant. Daily tasks such as making a peanut butter sandwich
for a non-allergic family member can be hazardous to the peanut-allergic member if the
knife used to spread the peanut butter has left a minimum amount of peanut on the cheese
sandwich. While allergen cross-contamination is known in the home environment, the
production process of the manufacturer is unfamiliar territory. Consumers can only guess at
the allergen management. Hence, the risk of allergen cross-contamination with regard to
processed food has to be considered as a hidden danger to allergic consumers.
The Likelihood of An Allergic Reaction
The next step is to identify the probability that cross-contamination causes an allergic
reaction. Several aspects need to be considered (Spanjersberg et al. 2007). Firstly, the
likelihood exists that a trace amount of allergen will contaminate a finished product.
Secondly, if a product has in fact been contaminated with an allergen, the probability that an
allergic reaction will occur depends on whether the person consuming the product is
sensitized. Clearly, foodstuffs available in supermarkets have a wide range of buyers, most
of whom are not allergic. Statistically viewed, only a portion of the public has been
clinically diagnosed with a food allergy.7 Research estimates that the prevalence of IgE-
mediated food allergies in children is up to 8% and, in adults, between 1 and 3%. However,
the percentage of people who perceive themselves to be allergic to certain foodstuffs is
much higher. This may be related to the fact that most food-adverse reactions are not caused
by a food allergy but by food intolerance. Furthermore, it is suggested that the prevalence
has increased in the last few years (Asero 2007; De Blok et al. 2007; Miles et al. 2005).
Due to the preponderance of diverse and unreliable methods of diagnosing food allergies,
clear evidence of their true prevalence is absent. However, this will change. In 2005, the
EU-funded research project EuroPrevall embarked upon a series of studies whose ultimate
goal is to improve the quality of life for food-allergy sufferers. Establishing objective data
on food allergies in children and adults across Europe is one of the project’s objectives
(Mills et al. 2007).8 Thus, the probability that allergic sufferers will eat that particular
product is also relevant. Thirdly, even though an allergic person has consumed a
problematic product, an allergic reaction does not automatically result. The allergenic
residue must also be of sufficient quantity to trigger an adverse reaction.
Several studies have examined the presence of undeclared allergens in food products.
One study showed that a chocolate bar without a ‘may contain peanut’ statement or without
peanut in the ingredients list is not necessarily a guarantee of a peanut-free chocolate bar.
Nearly 31% of chocolate bars from Western Europe and 62% of those from Eastern Europe
contained detectable peanut levels (Vadas and Perelman 2003).9 The results of a Dutch
study also confirm that products lacking a declaration of allergen can in fact have traces of
allergen in them (Voedsel en Warenautoriteit 2007).10 Of the products with a precautionary
label, 35 of the 77 tested had peanut or casein. Another peanut study showed far less cross-
7 Food allergy is defined as an adverse reaction to food, mediated by the immune system. Sufferers produce
IgE antibodies to one or more allergenic proteins in the food.
8 For more information on the project: http://www.europrevall.org.
9 The levels of detectable peanut went up to 245 ppm peanut protein.
10 Fourteen of the 44 tested products with no declared peanut contained a detectable level of peanut. Twenty-
nine of the 64 tested products without casein on the label contained casein.
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contamination; of the 179 food packages bearing an advisory statement, such as “may
contain” or about shared equipment, only 13 products had detectable levels of peanut. As
the levels varied substantially, it is probable that not all amounts would have elicited
adverse reactions (Hefle et al. 2007).11
The Seriousness of the Injury
Allergic individuals appear to vary widely in their degree of sensitivity to a specific
allergen. It is generally agreed that a relationship exists between dose of allergen and
severity of injury. Individuals who react to very low doses are those most at risk of a severe
reaction (Hourihane and Knulst 2005). Especially with regard to peanuts, very low doses
are able to elicit critical symptoms. This means that taking just a mouthful of a food product
could be hazardous (Wensing et al. 2002). Within the group of allergic people, the majority
are not highly sensitive. As a result, they can be exposed to low levels of an allergen and
experience either no reaction at all or a mild one. Common symptoms of food allergy are,
for example, itching of the mouth, eyes, and throat, nausea, vomiting, diarrhea, skin rash,
and asthma. A severe allergic reaction is anaphylactic shock. It starts off with symptoms
such as a swelling of the lips, shortness of breath, rapid fall in blood pressure, and even loss
of consciousness. This can be fatal if not treated quickly. The most common causes of
anaphylactic shock are peanuts and nuts. Other allergens such as milk have the potential to
cause it as well (Bock et al. 2007).
Although it is recognised that exposure to even minute amounts of allergenic food can
elicit adverse reactions in people, no hard data exist on the minimum doses of an allergen
required to produce an adverse reaction. Such doses are referred to as threshold doses, and
they define the lowest observed adverse effect level, an amount of a specific food that
would elicit objective symptoms in highly sensitive individuals. The threshold doses differ
per allergen. Several studies have reported results with regard to threshold doses for
allergens such as peanut, egg, and cow’s milk (Bindsley-Jensen et al. 2002; Wensing et al.
2002). These findings are of a preliminary nature, and uncertainty with regard to
determining thresholds still exists for various reasons. One is that a variety of different
clinical protocols were used to generate data, which makes it difficult to compare the
existing data. Another factor is that data on minimal amounts causing highly severe
reactions is missing because most physicians exclude the most sensitive individuals from
the clinical experiments (EFSA 2004; Taylor et al. 2002). Consensus on a standardized
clinical protocol has been developed, on the basis of which an estimation of threshold doses
for allergenic foods can be carried out with more certainty. The data on these low-dose
challenge trials should become available in the near future (Taylor et al. 2004).
The Use of the Food Product
As follows from above, a food product which is cross-contaminated presents no hazard to a
vast majority of the population when it is used as intended. On the other hand, the mere
consumption can elicit adverse reactions in allergic individuals. The only treatment
available against food allergies is complete avoidance of the allergen, since the risk of
cross-contamination can already materialize during normal use.
11 The products tested were nutrition/meal bars, cereals/cereal bars confectionery products, snack foods,
frozen desserts, instant/quick meals, baking ingredients, and bakery products.
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The Avoidability of the Risk of Cross-Contamination
Allergen cross-contamination can occur for a number of reasons, all of which are linked to
how a manufacturer runs the production process. For example, given that a producer
manufactures a variety of products within the same factory, he might choose the option of
scheduling several of these to be processed on the same production line. If the allergenic
ingredient is powder, then wet cleaning cannot be carried out. It is possible that the removal
of the allergen on the basis of a dry cleaning will prove to be ineffective. As a result, the
powder can contaminate whatever is being produced afterwards. Even if there is no shared
production line, cross-contamination may still occur as a result of shared utensils, rework,
air supply, cleaning practices, staff hygiene, manual processes, and shared storage and
transport of products with and without allergenic ingredients (FSA 2006; van Ravenhorst
2007, p. 13). Altering the schedule of the production runs, separate and clear storage of
allergenic raw materials, physical separation between production lines, and staff training are
appropriate measures to reduce and avoid cross-contamination. Adequate recall procedures
contribute as well to the prevention of injuries resulting from cross-contamination.
After reading the above, one might feel the answer to how to completely avoid allergen
cross-contamination would be simple. A dedicated factory used only to manufacture
allergen-free products would solve the problem (FSA 2002a, p. 54). However, giving
consideration to the cost and practicability of taking these safety measures, prevention of
cross-contamination becomes less feasible. For small food businesses, it may not always be
possible to segregate the production environment of foods with allergenic ingredients. The
buildings are too small, the equipment is too old, or rearranging the layout of the production
area is too expensive. Likewise, a building dedicated production facilities is an enormous
financial burden on producers who manufacture a variety of food products.
A less rigorous approach to avoid harm resulting from cross-contamination is to allow
small levels of allergenic contamination that would probably not harm the vast majority of
allergic consumers (Crevel et al. 2007, p. 692). Currently, the food industry maintains a
zero tolerance level for allergens, since there is little accurate information on the threshold
doses for common allergens. Without a consensus on what the exact threshold doses are, it
is difficult for manufacturers to manage the risk of cross-contamination (Taylor et al. 2002,
p. 25). When threshold levels are established, the food industry and regulatory agencies will
be able to create an acceptable level of safety for the vast majority of allergic consumers. If
a level can be identified that does not elicit an adverse reaction in the group tested, then
statistically, it is highly probable that 90% of the allergic consumers will not react to this
dose of the particular allergen. It must be noted that on the basis of this approach, not all
allergic consumers would be protected (Taylor et al. 2004, p. 694).
Hence, avoidability of harm refers not only to the theoretical side in terms of whether it is
possible to actually prevent cross-contamination but also to the practical side of product
safety. The financial ability of a manufacturer to bear the cost of a safer version of the product
also determines to what extent a manufacturer will minimise the risk of cross-contamination.
Product Liability under the European Directive
Liability Without Fault
Following the discussion of the circumstances of the present case, it now boils down to the
actual examination of the nature of the Directive and the ensuing liability questions.
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Directive 85/374/EEC on liability for defective products (hereafter “the Directive”) came
into effect in 1985 and led to the introduction of a new concept of liability in the Member
States of the European Community.12 The Directive constitutes an internal market measure
designed to harmonize within its scope a liability system without fault on the part of the
producer. Hence, proof of negligent conduct on the part of the producer is not required. The
Directive’s guiding principle is that a producer is liable for damage caused by a defect in his
product. What constitutes a defect or, in other words, what product can be considered defective
is of crucial importance for determining liability. Article 6 states that a product is defective
when it does not provide the safety that a person is entitled to expect, taking all circumstances
into account, including the presentation of the product, the use to which it could reasonably be
expected to be put, and the time when the product was put into circulation.
This test of consumer expectations gives rise to two potential obstacles in determining
defectiveness in the allergen case. Firstly, a civil court will instantly wonder what level of
safety consumers are entitled to expect of food products. Are consumers entitled to expect
that all food products from the supermarket are 100% allergen free if the allergen is not
declared in the ingredients list? Or can customers with allergies be expected to view each
single food product as a possible threat to their lives, even if there is no warning? Secondly,
another problem arising from the application of the consumer expectation test is whether
the Directive protects the safety interests of food-allergic consumers, in particular since the
test of defectiveness depends on the safety expectations of the public in general.
A Special Category of Consumers
One potential hurdle to overcome is the application of the consumer expectation test to a
particular group of people in society. Article 6 of the Directive stipulates that the
defectiveness of the product should be determined with reference to the lack of safety that
the public at large is entitled to expect. This is an objective test. It is not the safety
expectations of the injured claimant in a particular case that are decisive but those of
persons in general. Thus, it seems that the test refers to the concept of the safety
expectations of the normal, average consumer (Howells 1993, p.12). This may be
problematic in the present case given that the average consumer does not have a food
allergy. Furthermore, it is plausible that the safety expectations of food allergic sufferers
depart from those who are not allergic.
There are good grounds to believe that the safety interests of this special group of people
need to be protected. Although allergic consumers are in the minority, they do form part of
the general public. Available statistics point to a significant number of people allergic to
food in Europe. Moreover, the issue should not just be substantiated quantitatively.13 The
severity of the injury caused by an adverse reaction should carry weight too, especially for
those people who are highly sensitized and whose injury from ingesting even a small
amount of allergen is severe or fatal. It seems likely that in view of the commonness of food
allergies among consumers and the potential severe reactions, the general public would
expect those persons to be protected, at least to some extent. Furthermore, public food
12 Council Directive 85/374/EEC of 25 July 1985 on the approximation of the laws, regulations, and
administrative provisions of the Member States concerning liability for defective products (OJ 1985, L 210/29).
13 Several American courts have addressed a similar problem by adopting a substantial number test in cases
of allergic reactions. According to comment k of the Third Restatement of Torts, it is important that the
allergic reaction of the claimant is not unique. The more severe it is, the more justified is the conclusion that
the number of persons at risk need not be large to be considered substantial (Owen 2005, p. 596).
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safety regulations indicate the need to protect the allergic consumer. Over the last few years,
adverse reactions to foods have become recognized as a public health problem. New legal
developments in food safety, such as the requirement to label the common allergens,
indicate the importance of this group. Article 14 (2) of the General Food Law provides that
food is deemed to be unsafe if it is considered injurious to health or unfit for human
consumption.14 To determine this, consideration must be given to the particular health
sensitivities of a specific category of consumers, where the food is intended for that
category.15 It seems to follow from this paragraph that food manufacturers are obliged to
take into account the interests of consumers who may experience allergic reactions to their
products, as they are foreseeable product users.16
The Concept of Defectiveness
The Consumer Expectation Test and its Flaws
The next important step in determining whether a product is defective consists of assessing
the level of safety that allergic consumers are entitled to expect from foodstuffs that have no
allergen labelling. Unfortunately, the execution of the consumer expectation test contains
weaknesses, as many commentators have already pointed out (Clark 1989, p. 29; Howells
1993, p. 11; Henderson and Twerski 1999; Stapleton 1994, p. 234). Instead of providing the
answer to the question of when is a product defective, its application raises the subsequent
question of how much safety is the general public entitled to expect of a product. Especially
with regard to complex technological products, the test provides scant guidance, as
consumers have difficulty assessing the safety level of such products. Failing to provide
absolute safety is not the criterion for assessing product defectiveness (Whittaker 2005,
p. 485). Similarly, a product is not defective simply because the use of it involves risks and
one of those risks materializes and causes harm to a consumer. However, the area between
absolute safety and no safety is grey. Just such a difficulty arises in the case at hand as well.
Does a food product carrying a risk of allergen cross-contamination provide the safety that
people are entitled to expect or will these safety expectations be met only if an adequate
warning is present? Or could it even be argued that a food product would only be regarded
safe if the risk of cross-contamination were fully eliminated? Furthermore, the Directive
states that all circumstances must be taken into account to assess whether there is a defect,
but it has left open how to determine what circumstances are of relevance as well as in what
way the relevant circumstances ought to be balanced against each other. As a result, the
outcome of a judgement can be unpredictable, a consequence which can undermine the goal
of European harmonization of product liability.
A Distinction Between Product Defects
A common way to tackle the problem of establishing the defectiveness of a product is by
exploring what type of deficiency the case at hand covers. Although the Directive does not
distinguish between three types of product defects, doing so provides a useful tool that is
14 Regulation (EC) no. 178/2002 (OJ 2002, L31/1).
15 Paragraph 4c of article 14.
16 Also within the definition of a safe product under article 2b of the General Product Safety Directive 2001/
95/EC (OJ 2002, L11/4), specific categories of consumers at risk must be taken into account.
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used in the European literature and in case law as well. In American product liability law, three
product defects have been formulated: design, manufacturing, and warning.17 Manufacturing
defects exist when the product departs from its intended design even though all possible care
was exercised in the preparation and marketing of the product. Design defects occur when the
foreseeable risks of harm posed by the product could have been reduced or avoided by the
adoption of a reasonable alternative design, and failure to use the alternative design renders
the product not reasonably safe. Warnings or instructions for use are defective when the
foreseeable risks of harm posed by the product could have been reduced or avoided by
reasonable instructions or warnings, and their omission renders the product not reasonably
safe.
What is the defect in this case? As follows from the description of the allergen cross-
contamination case, a food manufacturer has two precautions at his disposal to reduce and
even avoid the risk. Firstly, one could contend that there is a defect in design, as the
possibility of cross-contamination is a fundamental and recurring problem in the production
process. The products all carry the risk of cross-contamination as a result of the way in
which the food manufacturer has designed the production process. The risk of cross-
contamination can be managed by a producer. Hence, a producer’s decisions can be treated
as a potential design defect. It must be noted that it is also possible to treat it as a
manufacturing defect because the food product has been contaminated with an allergenic
ingredient during the production process. Indeed, in practice, the theoretical distinction
between manufacturing and design defects is not always clear. In the end, however, it may
be best to look upon this issue as one of a design rather than of a manufacturing defect
because theoretically a producer has the power to choose the alternative of avoiding the risk
completely and choosing the level of safety. Secondly, it is likely that the number of
accidents resulting from the risk of cross-contamination will decrease if a product warning
is given by a producer. In other words, the defectiveness of a food product without a “may
contain” statement may depend on its design or be a result of the absence of warning.
To assess whether a product is defective in design or as a result of the absence of an
adequate warning, the circumstances of the case must be balanced against each other
according to article 6 of the Directive. The Directive leaves it to the discretion of the court
to decide what circumstances are of significance in a particular case. Article 6 does,
however, offer some guidance by specifying three circumstances. These include the
presentation of the product, the reasonably expected use of the product, and the time when
the product was put into circulation. However, those factors alone will not help a judge to
make a sound judicial analysis of the product’s defectiveness. Circumstances such as the
likelihood that a danger emerges, the degree of harm arising from that, and the knowledge
and the obviousness of the danger are of importance, too. Of interest is whether the
Directive permits the use of the avoidability of the harm by the manufacturer as a relevant
factor. This factor represents the yardstick of fault-based product liability. Whereas strict
liability focuses on the safety of the product, fault liability assesses the negligent behaviour
of the manufacturer. The vital question is whether this risk created by the food manufacturer
is reasonable in view of the level of care taken. Hence, it applies a risk-utility test to
determine defectiveness. In assessing consumer safety expectations, many courts apply
fault elements to the defectiveness standard, such as taking into account the avoidability of
the harm and the cost and practicability of a safer product. Indeed, courts and scholars have
recognized that the assessment of liability under both theories proceeds rather identically
with regard to design and warning cases (Lord Griffiths et al. 1988; Miller and Goldberg
17 Restatement (Third) of Torts: Product Liability § 2a,b,c.
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2004, p. 354; Stapleton 1994, p. 236; Whittaker 2005, p. 488). Whether a product is
defective due to an unsafe design is related to whether a producer has taken sufficient
precautions to reduce or to avoid the harm associated with the design. Similarly, the
question of whether the absence of a warning renders the product defective or if there is a
duty to warn under fault liability is considered on the basis of similar circumstances.18
A Distinction Between Standard and Non-standard Products
By contrast, other scholars have argued that the liability system of the Directive does
impose liability without fault (Deards and Twigg-Flesner 2001; Taschner 2005).19
Especially Justice Burton holds the view that the avoidability of the harm and what a
manufacturer could and should have done differently are not of relevance, as they do not
correspond to the purpose of the Directive, which is to provide a liability system without
fault. Taking such factors of reasonableness into consideration would mean reintroducing
fault-based liability by way of the back door. He introduces an approach to defectiveness
based on a distinction between standard and non-standard products. In view of the fact that
his way of thinking has grabbed the judicial headlines, it is interesting to examine if and
how liability can be established in the present case. Burton J’s approach to defectiveness
will be discussed after the sections that deal with the liability question regarding a design
defect and/or warning defect.
A Design Defect
The American Restatement of Torts provides a helpful definition to explore whether there is
a design defect in the case at hand. According to this definition, a design defect occurs
when the foreseeable risks of harm posed by the product could have been reduced or
avoided by the adoption of a reasonable alternative design, and failure to use the alternative
design renders the product not reasonably safe.20
In applying this tool, a civil court must first determine what precautions the particular
manufacturer has taken to reduce the risk of cross-contamination. An acceptable level of food
safety can be achieved on the basis of the implementation of a safety management system that
is required under EU food safety law. The responsibility to apply the HACCP principles
properly to allergens rests with the food producers. As mentioned above, EU regulations offer
little guidance, as those obligations are described in general terms. Best practice guidelines
about allergen risk management are available but are provided voluntarily.
Normally, EU food safety law can provide a clear starting point for a civil court to
decide what level of safety is at least required, as regulations and standards usually set a
minimum level of safety. Although the Directive only provides a defence of regulatory
compliance in cases of detailed provisions, it seems that fulfilling all the applicable food
18 The new American Restatement has also accepted the view that warning and design defects need to be
defined in terms of reasonable safety (Owen 2005, p. 332). As for manufacturing defects, it is generally
agreed that strict liability is well suited. Since the product has failed to meet the manufacturer’s own
standard, it will no doubt be considered to have failed to meet consumer expectations (Stoppa 1992, p. 211;
Van Dam 2006, p. 377). For example, the German case of the exploded water bottle: BGH 9 May 1995, NJW
1995, 2162.
19 Justice Burton in A. & Others v National Blood Authority [2001] 3 ALL ER 289, para 63.
20 Restatement (Third) of Torts: Product Liability § 2b.
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safety law requirements is a relevant indication of non-defectiveness. Conversely, non-
compliance indicates that a product has failed to meet the required level of safety.21 It is
uncertain whether this reasoning is valid in respect of voluntary guidelines (Fairgrieve and
Howells 2007, p. 972; Miller and Goldberg 2004, p. 380).22 Guidelines usually serve as a
means of assisting businesses. Consequently, the decision is left to the manufacturer to
choose this approach or another guideline. It is more conceivable that a product is rendered
defective if food safety management taking account of the potential hazard of allergens is
absent. In all cases in which a producer has in fact implemented a HACCP-based food
safety system, defectiveness will turn upon whether the producer has created an appropriate
level of safety. Since there are no mandatory requirements with regard to the extent to
which the risk of cross-contamination needs to be avoided, it is for the court to determine,
with the benefit of hindsight, what level of safety should have been achieved according to
civil safety standards.
Defectiveness does not depend merely on the existence of a safer alternative of the
product or on whether a manufacturer could have produced a safer product (Stapleton 1994,
p. 259). The financial costs associated with the production of a safer alternative, as well as
the practicability of the alternative design, form part of the burden of the costs of
precautions. Defectiveness is established if the manufacturer has failed to implement the
safer design, for which the safety benefits are outweighed by its costs (Owen 1996).23
An alternative design available to manufacturers is a food product for which the
potential presence of the risk of allergen cross-contamination has been avoided. The only
way to ensure such a safety level would be to adopt an allergen-free production
environment: for example, the creation of a closed area with a production line that handles
only allergen-free products. In circumstances where the risk of cross-contamination can
prove fatal to an allergic consumer, full segregation would be the only solution (FSA
2002a, p. 54). Cleaning the production lines will not suffice. Such an alternative would be
costly to implement and, for many businesses, also less practicable in view of the number
of products processed in the factory. It would probably entail food businesses having to
close down because they are not financially capable of fully eliminating the risk of cross-
contamination. As a result, products would disappear from the market, and the vast majority
of the public would no longer be able to buy and enjoy them. Furthermore, segregation is
currently the only reliable solution, as there is a lack of scientific evidence concerning the
minimum amounts of allergens needed to trigger adverse reactions in sensitive individuals.
As long as there is no definite consensus on the threshold doses, it is difficult for food
businesses to manage the risk in an acceptable way. Nevertheless, science offers means for
risk assessment (Spanjersberg et al. 2007).
Requiring manufacturers to implement this alternative of complete avoidance of cross-
contamination means in essence that allergic consumers are entitled to expect absolute
safety. Thus, allergic consumers would be entitled to expect that food products that have no
“may contain” statement or other allergen-related information on the label are indeed 100%
free of allergens. Based on this assumption, a food manufacturer is liable for the sole reason
21 For example, the judgment of the Dusseldorf District Court of 30 November 2005, 10 O 144/04, NJW-RR
2006. See Lenze (2006), p. 20.
22 For example, the judgment of the English Court of Appeal in Tesco Stores Ltd v Pollard [2006] EWCA
Civ 393. See Webber (2006), p. 21. The Court of Appeal held that violation of the voluntary standard did not
lead to a conclusion that the product is defective.
23 Such an approach resembles the one of Judge Learned Hand in the famous case United States v Carroll
Towing Co (1947) 159 F. (2d) 169, 173.
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that an allergic consumer has suffered injuries, as it turned out that the product did contain an
allergen. All allergic consumers would be protected under the scope of the Directive,
irrespective of their sensitivity and the severity of the reaction. As noted above, the Directive
does not impose a system of absolute liability.24 Consequently, an absolute level of safety,
and hence full segregation, is not reasonable because the financial costs and impracticality of
eliminating the risk of cross-contamination outweigh the safety benefits achieved.
A reasonable alternative, for example, could be to minimize shared equipment and to
schedule the manufacture of an allergen-free product before the production of foodstuffs
containing allergenic ingredients. Such an adjustment is mentioned in the voluntary
guidelines. As a result, the probability that the risk of cross-contamination occurs will have
been reduced. If a producer fails to take such steps, the safety benefits resulting from the
alteration would probably necessitate incurring the costs of the alternative design. Although
this new production process design probably does not protect the most sensitive allergic
consumers, it will protect the majority from experiencing severe reactions. However, this
cannot be concluded with certainty. To determine the acceptable level of safety, reliable data
on the threshold levels and on the prevalence of food allergy are important. An approach to
create an acceptable level of safety would be to determine an upper limit of the amount of
an undeclared allergen that is allowed to be present in a food product. However, these upper
limits are only meaningful if on the basis of reliable scientific information it can be
concluded that they sufficiently protect the majority of allergic consumers. As explained
earlier, a consensus on firm threshold doses has not yet been reached (Crevel et al. 2008,
p. 599). In the absence of such data food businesses are being plagued by uncertainty as to
whether they have assessed the risk adequately. It may be possible—certainly given the
EuroPrevall project—that in the near future, a further consensus will be reached with regard
to the threshold doses for the most common allergens. This could influence liability, as
article 6 stipulates that the state of science at the time the product is put into circulation is
decisive. Especially with regard to food products with an expiry date, manufacturers must
keep abreast of the latest technical and scientific developments.
In the event that a judge decides that the food product without a “may contain” statement
is defective, escaping liability by invoking the development risks defence of Article 7(e) of
the Directive will, in all probability, be unsuccessful.25 The risk of cross-contamination is
known to manufacturers, and complete avoidance is possible as described above. Alleging
that the costs of providing a safer alternative design of the production process are too high
is not a convincing argument in this respect. Furthermore, even if it is not possible to
discover the existence of contamination of a specific food product on the basis of the
scientific and technological knowledge at the time when he put the food product into
circulation, in the end, complete avoidance by full segregation is still optional.
AWarning Defect
A Failure to Warn Case
Due to uncertainties with regard to the prevalence of allergens and the threshold doses, a
warning statement could be a good safety measure. But does the Directive require
24 Blood products are an exception to this rule.
25 See the judgment of the European Court of Justice C-300/95, ECR 1997, p. I-2649 (Commission v UK).
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manufacturers to alert the public, particularly allergic consumers, of this risk of cross-
contamination in view of its small likelihood?
Within the meaning of a consumer expectation standard, the presentation of the product
seems to be of great significance. Referring to this circumstance as a determinant of safety
expectations is not without reason. Indeed, the way in which a manufacturer presents a
product can strongly influence a consumer’s perception of its safety. It is recognized that
this factor should be broadly interpreted, suggesting that warnings, instructions for use,
advertising, and other information that may influence consumer safety can contribute to the
adoption of defectiveness (Howells 1993, p. 37; Miller and Goldberg 2004, p. 371). Safety
expectations can be lowered by the presence of product warnings that imply that the
product’s use involves risks. Furthermore, it might create a false sense of safety when
important safety information is missing or misleading. It could follow from this that every
risk, irrespective of its size, must be communicated to consumers, as this enables them to
adjust their safety expectations. Given that there is a hidden danger and that public
knowledge thereof is lacking, one might judge in favour of the allergic consumer and
establish defectiveness based on the conclusion that the absence of information on this
danger renders the product unsafe. Hence, this also constitutes a flaw in the consumer
expectation test. Such a strict application should not be considered appropriate, as other
factors need to be considered as well. Those that need to be balanced in the process of
determining defectiveness are in essence identical, as in a failure to warn case under
liability in negligence (Stoppa 1992, p. 221).26 In fault liability, it is generally agreed that
the greater the likelihood of damage, and the more practicable the measures to guard against
it, the more comprehensive is the warning that will be required (Miller and Goldberg 2004,
p. 583). The relevant factors must be weighed in order to assess whether the benefits of
providing a “may contain” warning are outweighed by its costs.
The Benefits of the Warning
Several factors point to the desirability of providing information about cross-contamination
on the label. Firstly, it cannot be concluded from the presentation of the food product that
there is a risk of cross-contamination attached to its use, as there is no allergen information
on the package. Secondly, a consumer has no knowledge of the potential presence of
allergens in the processed product. It should be noted that it is possible that the safety
expectations regarding one food product will be different for another. It is not strange to
expect that, in the absence of a “may contain” label, there are no sesame seeds or nuts in
chewing gum.27 It may be easier to imagine that a currant bun might be infected with a
trace of nut.28 Nevertheless, in both cases, consumers do not have a clear view of what goes
on in the food business. They lack accurate information concerning the diversity of
products being made in the factory, the manufacturing conditions, the cleaning procedures,
and so on. Furthermore, although consumers are currently being confronted with products
that carry advisory statements, they are still not able to assess the risk of cross-
contamination of products that have no advisory labelling. Thirdly, allergic consumers
26 See, e.g., Lenze (2003), pp. 44–45 for a discussion of a judgment of the Austrian Supreme Court, where
the approach of the Court towards a warning defect hardly differed from the traditional concept of
reasonableness.
27 A package of Stimorol Fusion gum, bought in The Netherlands, carries the statement that it may contain
traces of sesame and nuts.
28 A bag of currant buns from the Dutch supermarket Albert Heijn contains the statement that the product is
made in a factory that also handles nuts.
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benefit from this warning statement since they are liable to suffer physical harm as a result
of normal use. Allergic consumers can sustain severe adverse reactions, even fatal injuries,
from minute amounts of an allergen. A bite of something can prove fatal if the person is not
treated quickly and properly. The only remedy for food allergies is avoidance, and clear
labelling is a positive step. Moreover, the warning can be an effective means to reduce the
risk, as it allows consumers to easily avoid a potential adverse reaction. From a
manufacturer’s viewpoint, putting a warning statement on a food label can compensate
for the inability to adequately assess the risk of cross-contamination. Its use might also
reduce the cost of recall measures that would have had to be taken in the absence of a “may
contain” statement.
The Costs of the Warning
Cross-contamination can cause serious injuries. However, the group of allergic consumers
who experience severe reactions from trace amounts of an allergen appears to be smaller
than the majority of allergic consumers. In addition, the probability that a product becomes
contaminated in the factory is small. Nevertheless, as explained above, this probability also
depends on what steps a manufacturer has taken to reduce the likelihood.
Furthermore, not only are expenses involved in the design of a “may contain” warning,
but an obvious consequence of providing such information could be a decrease in profit, as
allergic consumers would probably stop buying the product (Viscusi 1990, p. 602).
Additional Costs of the Warning
In addition to the costs described above, other potential disadvantages are associated with
the presence of a “may contain” statement. These costs are based more on a general level.
A widespread use of precautionary statements about the risk of cross-contamination can
lead to adverse effects for allergic consumers. To begin with, an extensive use of “may
contain” labelling leads to a restricted food choice, which in turn could eventually give rise
to an unhealthy diet. This continuous attention to avoiding foodstuffs to which consumers
are or may be allergic has a negative impact on the quality of life (De Blok et al. 2007,
p. 734). In addition, too many “may contain” labels can result in a devaluation of the label
itself. Research indicates that there is a group of allergic consumers who disregard these
labels. An American survey revealed that consumers with food allergies increasingly ignore
advisory statements and consume these potentially dangerous food products. Consumers
paid less heed to the warning labels in 2006 than they did in 2003 (Hefle et al. 2007.
p. 172). A study undertaken by the British Food Standards Agency likewise reports that
some allergic consumers regularly ignore these statements on food packages, thus putting
themselves at potential risk (FSA 2002b). Adolescents and young adults in particular
exhibit risk-taking behaviour (Miles et al. 2006, p. 796; Sampson et al. 2006). It could also
be that such a proliferation of warnings contributes to a warning overload (Geistfeld, 1996,
p. 351; Noah 1994, p. 381). Too many “may contain” warnings in the world may result in
consumers paying less attention to them (Wogalter and Vigilante 2006, p. 258).
Conclusion
Since the facts of each case are unique, it is difficult to answer unequivocally the question
of when is a “may contain” warning needed to make a food product reasonably safe. It
might be that in the aftermath of an incident, a civil court decides that the absence of a
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“may contain” warning renders the food product defective, given that the harm done to the
consumer was severe. It is most likely that only such a claim would be taken to court as
opposed to a claim of a consumer who suffered mild reactions. If the harm is serious or
fatal, courts usually require considerable precautionary measures, even if the risk itself does
not immediately indicate the need to warn. Courts often view the costs of printing a
warning as minimal, as a result of which the scales will almost always tip in favour of
warning (Owen 2005, p. 568; Rheingold and Feinglass 1996, p. 362).
A difficulty in this respect is that product liability law does not provide courts with a
proper answer to the question of when can a relatively small risk be considered sufficiently
large to warn about. In fact, the Directive implies the opposite by emphasizing the
presentation of the product. As a result, manufacturers might be encouraged to enumerate
all the dangers associated with the use or foreseeable misuse of the product, irrespective of
the size of the risk (Clark 1989, p. 100; Howells 1993, p. 38). If many manufacturers allow
themselves to be carried away in this manner, the use of “may contain” labelling may even
result in adverse side effects such as an unnecessary restriction of the food consumption of
allergic consumers, as well as a dilution of the content of a “may contain” warning and of
product warnings in general (Noah 1994, p. 374). However, courts cannot easily determine
and apply such costs to the balancing process. Consequently, they will probably not be
treated as additional costs, and the increased safety benefits will outweigh the costs of
providing a warning (Geistfeld 1996, p. 335).
It may well be that civil courts also attach value to the existing scientific uncertainty with
regard to the actual risk of cross-contamination. Considering the circumstance that the
precautionary principle is imbedded in the General Food Law, a court could be convinced
that a warning is needed to render the product reasonably safe. Nevertheless, this can be
reviewed when firm evidence on threshold doses has been established.
Risk Analysis of Courts
From the above, it follows that claimants will probably allege warning defectiveness, and it
appears that courts will render the food product defective as a result of the absence of a
“may contain” warning. However, a judge must be careful not to deliver this ruling too
eagerly. Even though each case is decided on its merits, the ruling that a food product
without a “may contain warning” is defective can give out a misleading signal to
manufacturers. Manufacturers might interpret such a decision in such a way that they need
to provide a warning as well, in spite of the fact that, on the basis of their circumstances, a
warning is legally unnecessary or notwithstanding that there are more effective safety
measures available. It promotes an abundance of “may contain” warnings and limits the
food choice of allergic consumers. How unfortunate it may be for the individual claimant,
denying liability cannot be ruled out.
A court’s guiding principle should be to prevent the misuse of “may contain” warnings.
“May contain” labels should be used only on the basis of a responsible risk assessment and
not in case of very small risks or as a means to cover up a design defect. Where possible, a
court should rule in such a way as to create the incentive for manufacturers not to settle for
a “may contain” label but to seek for other feasible options to reduce the risk of cross-
contamination. Therefore, it is essential that courts evaluate the allergen risk assessment and
management system of the defendant. How did the manufacturer assess the probability of
cross-contamination? Did the manufacturer do proper tests to find out whether and to what
extent the products are contaminated? Did the defendant receive complaints from
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customers? Did he take measures into account that could reduce the risk, such as making
changes in the production process, the recipe, working procedures and so on? If necessary,
an independent expert in the field of allergen risk assessment can be appointed in order to
make the balancing process of courts more robust. Such a thorough examination will enable
courts to conclude on a case to case basis that, having regard to the trivial risk, consumers
were not entitled to expect a warning or that in view of the real risk, consumers were
entitled to expect a warning.
The importance of a good risk assessment is reflected in food safety law.29 Under the
HACCP approach, cross-contamination needs to be identified and controlled. When
monitoring indicates that the hazard is not under control, corrective action is necessary.
There are models on the basis of which this risk can be assessed, for example the
probabilistic model (Spanjersberg et al. 2007).
A Non-standard Product
Although in my opinion, it would seem that courts decide this complex liability case on the
basis of the use of risk-utility factors within the consumer expectation test, the innovative
approach of Burton J. in the English Hepatitis C case also deserves attention.30 It may well
be that this approach will gain more prominence in the near future. In his attempt to create
an approach towards defectiveness that serves the purpose of the Directive and differs from
fault-based liability, factors of reasonableness are set aside. The test of defectiveness is
framed on the basis of a classification of standard and non-standard products. Standard
products are products that perform as the manufacturer contends. Non-standard products are
different from the standard product because they are deficient or inferior in terms of safety:
they have a harmful characteristic that caused the damage.31 Having characterized a product
as non-standard, the next step is whether the public at large accepts the non-standard nature of
the product, by taking into account the relevant circumstances. Whether it would have been
possible, practicable or costly to avoid the defect is not relevant to consumers’ expectations.
However, a risk-utility balancing can be applied in the limited circumstance of whether with
full information and proper knowledge the public does and ought to accept the risk.32
The judge treated the infected blood products as non-standard products because the
products contained the harmful characteristic (the virus). He argued that consumers do not
have to have knowledge of this risk. As a result, the judge concluded that the blood
products infected with hepatitis C were defective since the public at large was entitled to
expect that the blood transfused to them would be free from infection.33 In fact, he imposes
29 Article 6 of the General Food Law stipulates that food law shall be based on risk analysis. Also in respect of
non-food products, thorough risk assessment procedures have drawn the attention of the European Commission.
See for example, the Commission’s draft revised Risk Assessment Guidelines, which are specifically designed for
risk assessors from the Member State market surveillance authorities who are dealing with non-food consumer
products within the framework of the General Product Safety Directive 2001/95/EC.
30 A. & Others v National Blood Authority [2001] 3 ALL ER 289.
31 Para. 36 and 67.
33 A similar decision was made by the Amsterdam District Court 3 February 1999, NJ 1999, 621. The
District Court held that the general public is entitled to expect that blood products are 100% HIV-free,
particularly since blood products are vitally important and there is no alternative available, as well as the fact
that the risk of infection is estimated at one in a million and not of general knowledge.
32 Para. 68.
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a form of absolute product liability. This could also be the outcome in the present case in
the event that a judge regards a food product that contains a trace amount of allergen as a
non-standard product. If consumers do not have to have knowledge of the risk of cross-
contamination, then they are entitled to expect that food products are 100% allergen-free,
without taking into account the enormous costs of avoiding the risk or the unresolved
scientific questions. Such a judgement would certainly break with the current approach of
using risk-utility factors to determine consumer expectations. While under the latter
approach, a court might sympathize with the defendant and not require full segregation of
the production process of products without an allergenic ingredient, Burton J’s approach
might require just that.
A more suitable distinction is to view the absence of a may-contain warning as the
harmful characteristic. Then, the focus will be on the question of whether consumers ought
to accept the risk of cross-contamination. Warning the public of the risk of cross-
contamination would make the risk known and, as a result, probably acceptable to society
as well. The Directive emphasizes the relevance of product information. In addition,
providing accurate information to consumers is also high on the consumer policy agenda of
the European Commission, as it empowers consumers to make informed choices.34 On the
other hand, it remains unclear if and how Burton J. would consider the potential unintended
consequences of providing risk information, such as consumers’ information processing
abilities in general, the restriction of the food choice of allergic consumers, and the
evidence that people increasingly ignore these statements. Would such factors make the risk
unacceptable? It is expected that the answer will be in the negative, too, under Burton’s
method. The benefits of the information including its value under European consumer law
will probably outweigh the costs.
The Adequacy of an Allergen Cross-Contamination Warning
An Informed Choice Warning
The liability question is also interesting in cases where products have in fact been provided
with a warning that indicates the possible inadvertent presence of an allergen. It is generally
agreed that a product can be considered defective under the Directive as a result of the
presence of an inadequate warning. However, neither the text of the Directive nor a decision
of the European Court of Justice clarifies what governs an adequate product warning.
Nevertheless, fault liability with regard to the duty to warn adequately can offer some
guidelines. It is suggested that the adequacy depends on whether the warning allows a
consumer to adequately identify, assess, and consequently avoid or reduce the risk (Hodges
1993, pp. 108, 109; Miller and Goldberg 2004, p. 463). To achieve this, not only the
content of a warning but also its form must be designed in such a way that it allows
consumers to avoid the risk. In this case, it is important that the warning with regard to the
risk of cross-contamination is sufficiently prominent for allergic users to notice on the label,
that it is legible, and that consumers understand the risk accurately in order to use the
product safely.
34 Communication from the Commission to the Council, the European Parliament and the European
Economic and Social Committee. EU Consumer Policy Strategy 2007–2013 (COM(2007) 99 final).
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Warnings against the risk of cross-contamination differ from ones you will find in the
instructions for use of household appliances. Instead of explaining how to use the product
safely, they are such that they instruct allergic consumers not to use the product. The third
American Restatement sets forth a definition of informed choice warnings that can be
applied to the case at hand. Informed choice warnings are those that allow the consumer to
avoid the particular risk by making an informed choice decision not to purchase or to use
the product at all.35 This new comment states that a warning may be needed not only to
reduce the risk of harm but also to inform consumers of non-obvious and not generally
known risks that unavoidably inhere in using or consuming the product (Henderson and
Twerski 2000, pp. 15, 16). It follows that allergic consumers want this information so that
they can decide on the basis of a risk assessment whether to purchase and hence consume
the product. Although, ultimately, a “may contain” warning serves the goal of accident
reduction, it can be said that here the emphasis is mainly placed on providing accurate
information about the risk of cross-contamination to potential buyers who are allergic.
Form of the Warning
Naturally the form of a warning (i.e., its design) must be conspicuous and legible. Factors
that attract the attention of consumers are the positioning of the warning on the product
label, the size of the text, and the colours used. Its legibility largely depends on whether the
wording is easy to read as the result of a large letter size together with the contrast of the
wording against the background of the label.
The European labelling legislation on foodstuffs and allergens stipulates that the
information must be easy to understand and in a conspicuous place.36 The regulations do
not set any specific requirements on how the information should be presented.
Manufacturers thus have the freedom to determine the location of the warning and the
font size of the wording as well as other design factors. Most space on the label is usually
set aside for marketing information. As a result and due to limited space, only a small area
is left for information about the ingredients and the allergens. Even in cases were the
package is larger, it still takes time to find the information.
Several studies indicate that food labels do not meet the needs of allergic consumers.
The results of British consumer research show that allergic consumers are dissatisfied with
the presentation of food labels, as the allergen risk information is often hard to find and
difficult to read. For example, it reported the finding that only 2.6% of the food packaging
was dedicated to ingredient information and an average of 0.53% to allergen information
(FSA 2002a, p. 13). Other recent European studies also highlighted the problems of allergic
consumers with regard to the readability and visibility of the food label. Many comments
were made about the large amount of information on a package, the small font size of the
information, the poor colour contrast of the label, and the shiny packing material, all of
which made reading difficult (Cornelisse-Vermaat et al. 2007; Van Hengel 2007). In
addition, consumers complained about the absence of a standard approach for the labelling
of cross-contamination warnings (FSA 2002b, p. 42).
The British guidance document on allergen risk management and communication
advises manufacturers on how to provide allergen cross-contamination information to
consumers (FSA 2006, p. 27). It recommends putting the “may contain” warning close to
the ingredients list. Nevertheless, it must be clear to the consumer that there is a distinction
35 Restatement (Third) Torts: Product Liability Section 2 (c), comment i.
36 Article 13(2) of Directive 2000/13/EC.
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between mandatory information on the intended ingredients and information on potential
ingredients as a result of cross-contamination. This information can be listed in boxes or
panels. Moreover, allergic consumers preferred the allergen information to be placed above
the ingredients list, if possible with a symbol to make the warning more prominent
(Cornelisse-Vermaat et al. 2007, p. 117; FSA 2002b, p. 65). More labelling guidelines, set
up by scientific experts, for example, are readily accessible by food manufacturers.
Nevertheless, it is doubtful whether the labelling requirements are implemented properly in
practice. It is possible that food manufacturers are not willing to spend more money and
effort on the design of an adequate food label that takes into account the information needs
of consumers. This can change. A new proposal for a regulation with regard to food
information to consumers lays down several labelling requirements to improve the legibility
of mandatory food information, for example a minimum print size.37 Even though these
obligations pertain to mandatory and not voluntary label information, such as the risk of
cross-contamination, a judge can use these as a guiding principle when assessing the label‘s
legibility.
Content of the Warning
As regards the content of a warning, comprehension is an important indication of adequacy.
The meaning of the warning message must be understandable to consumers, and it must
allow them to assess whether the risk will affect them (Howells 2005a,b, p. 161). Hence, if
a consumer cannot accurately appreciate the risk on the basis of the information given, it
will be difficult to make an informed decision to buy and consume the product.
Factors that may influence the comprehension of a warning are the language in which
the risk is described and the explicitness of the information. A study reported that allergic
consumers have difficulty with unfamiliar terms or scientific jargon used to describe
allergens (Cornelisse-Vermaat et al. 2007, p. 117; Joshi et al. 2002, p. 1020). For example,
the word “milk protein” is preferable to the term “whey powder” or “casein” (Crevel 2002,
p. 943). Additionally, the use of the word “nuts” in a “may contain” statement can be
unclear to consumers, as it does not state which particular type of nut is involved. It may
not always be the case that several sorts of nuts and peanuts are used in a factory. Given
that it is known that some people are only allergic to specific tree nuts like hazelnut, walnut,
or almond, such labelling is confusing (FSA 2006, p. 29).
With respect to explicitness, the risk of cross-contamination may be misunderstood
because of the vague phrasing of the warning. It appears that allergic consumers are
uncertain as to what “may contain” statements mean for a person with an allergy (FSA
2002b, p. 5; Van Hengel 2007, p. 99). Indeed, the real risk of cross-contamination cannot be
concluded easily from the information provided. Is the probability that contamination took
place remote? And does it tell a consumer anything about the amount of the undesired
allergen present in the food product? Furthermore, various forms of labels are in circulation
to warn allergic consumers of cross-contamination. Not only statements such as “this
product may contain allergen X” or “this product may contain traces of allergen X” exist
but also “produced in a factory that also handles allergen X” or “made in a production area
that also uses allergen X” (FSA 2002a, p. 59). This variety of explanations can be
confusing to allergic consumers in the sense that it is unclear to what extent they pose
different levels of risks. An American survey demonstrated that the format of a statement
37 Proposal for a Regulation of the European Parliament and of the Council on the provision of food
information to consumers (COM(2008) 40 final).
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can influence consumers’ risk perception: 75% of the respondents said that they would not
purchase a product with a “may contain” statement. This is in contrast to 64% of the
respondents who reported not purchasing products with statements such as “manufactured
in a facility that also processes or uses allergen X” (Hefle et al. 2007, p. 174).
Changes to the content of cross-contamination warnings have been suggested by allergic
consumers. Some preferred the inclusion of more meaningful information to enable them to
make their own informed choice with confidence, such as the inclusion of the probability of
contamination. Others wanted clear negative statements, such as “not suitable for nut
allergy sufferers” or positive statements, such as “the product is nut free” (FSA 2002b,
pp. 67–70). One idea could be to apply a grading system using phrases such as “not suitable
for individuals highly sensitive to allergen X.”
Hence, a disadvantage of a cross-contamination warning is that the statement does not
specify the risk. The only way to avoid it would be to stay clear of the particular food
product with a “may contain” statement. As a consequence, it may be questioned whether
the allergic consumer is actually capable of an informed choice.
Conclusion
In view of the above, it follows that several points for improvement are applicable to food
labels in general. Neither the form nor the content of “may contain” labels satisfy the
information needs of the majority of allergic consumers. Even so, the question remains as to
whether the informed choice warning is considered defective under the Directive.
Paragraph 2 of article 6 stipulates that a product shall not be considered defective for the
sole reason that a better product is subsequently put into circulation. Equally, this assumes
that the Directive does not require a product warning to be designed in the best way
possible (Howells 2005a,b, p. 146).38
It is possible that a court is displeased with the way in which the “may contain”
statement is presented. However, it must be noted that the small magnitude of the risk does
not support the expression “the bigger the better.” Furthermore, consumers have indicated
that they want more detailed information about cross-contamination. A grading system to
express the risk’s diversity could enhance consumers’ risk perception. Nevertheless, a food
manufacturer has few available alternatives, since risk assessment is hindered by scientific
uncertainty. Thus, it appears that a “may contain” warning would not be deemed inadequate
under the Directive, despite the information needs of allergic consumers.39
Perhaps, the approach of Burton J. allows a judge to establish product defectiveness
more easily because of the view that warnings should not be used to waive or limit
liability.40 Article 12 of the Directive implies such a notion by stating that limitations or
exclusions of liability are prohibited (Howells 2005a,b, p. 146). For the rest, it remains
ambivalent how one must consider the adequacy of product warnings under this approach. To
determine whether the product accompanied with a warning imposes an acceptable level of
risk, use of negligence factors is permitted by Burton J. This reintroduces risk-utility factors
38 This is reflected in the English case Worsley v Tambrands Ltd., High Court [2000] PIQR P95. The judge
decided that the warning of toxic shock syndrome on a tampon box was sufficient even though the warning
could have been improved by design alterations.
39 The studies on consumers’ information needs indicate the actual expectations of consumers, which may be
too high. It must be borne in mind that the consumer expectation test addresses the legitimate safety
expectations.
40 A. & Others v National Blood Authority [2001] 3 ALL ER 289, para. 65.
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into the consumer expectation test as shown earlier. Consequently, both methods may lead to
a similar conclusion. Yet, imposing liability due to the use of the may contain warning as a
waiver would seem more in line with the spirit of a liability system without fault.
Summary
The liability aspects of the use of the labelling of allergen cross-contamination were
discussed in the previous sections. This type of precautionary labelling is provided on a
voluntary basis. The EU labelling requirements only apply to foodstuffs that intentionally
contain allergenic ingredients. The prevalence of food allergies in the general population
has been roughly estimated to be around 3% in adults and up to 8% in children. Thus, it
appears that a food allergy can affect the lives of a considerable number of people in
Europe, with effects ranging from very mild to potentially fatal. From this, it follows
logically that their safety interests have been acknowledged in European food law.
Two central questions have been answered. Firstly, it is discussed whether a food
product can be deemed as defective under the Directive in the event that a warning of the
risk of cross-contamination is absent and an allergic consumer has suffered injuries as a
result of the unintentional presence of an allergen. This liability question is approached
within the scope of a defect in design and a warning defect, since food manufacturers are
able to reduce the risk of cross-contamination by means of redesigning the production
process or by providing a warning statement. Thus, risk-utility factors have been taken into
account to assess whether the product failed to meet consumers’ expectations. With regard
to the existence of a design defect, there are safer alternatives available for manufacturers to
reduce the risk. One would be the creation of an allergen-free environment with production
lines that are only used to produce products that have no allergenic ingredients. However,
this implies an absolute level of safety, the costs of which will outweigh the benefits.
Pursuant to Burton J’s approach to defectiveness, it may well be that requiring full
segregation is the only correct decision. What relative level of safety must be achieved in
the production process is uncertain, as there is a lack of scientific evidence concerning the
minimum amounts of allergens needed to trigger adverse reactions in sensitive individuals.
Consequently, it is difficult for the industry and the government to draw firm conclusions.
Only after such thresholds can be determined if it is possible for food businesses to adjust
their allergen management to these levels and thus create an acceptable level of food safety
for the vast majority. Nevertheless, this uncertainty does not mean that it is permissible for
producers to sit still and await further developments. There are tools available to help
producers cope with these problems, and safety measures such as cleaning procedures or
changes in the production lines can reduce the risk.
As for this scientific uncertainty, producers and courts may currently consider a warning
to be an adequate safety measure even in cases where the risk is small. It is certainly
possible that a judge considers a food product defective where the risk of cross-
contamination has not been declared on the food label. The essential key elements for a
judge would probably consist of the circumstance that there is a hidden danger and that it
can cause severe injuries. Providing allergic consumers with information about the risk will
enable them to appreciate the risk and consequently behave accordingly. In addition, courts
probably assess the costs of making a product warning low. However, this may be the
wrong solution in view of the potential unintended effects of the use of such warnings.
“May contain” labels do not only restrict the food choices of allergic consumers but can
also lead to warning ineffectiveness when many food manufacturers provide them
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extensively and when consumers start to disregard them. Therefore, judges ought to be
cautious in establishing a warning defect. It is suggested that courts should take on the
mantle of a risk assessor and ascertain whether the risk assessment carried out by the
defendant is appropriate. Design defectiveness due to failure in implementing feasible
changes in the production process is preferred to the ruling that a warning renders the
product reasonably safe. In addition, a court should not be unaware of the possibility to
deny liability in case of a very small risk, albeit the unfortunate victim.
The second liability question concerned the adequacy of “may contain” warnings.
Consumer studies showed that these fail to meet the information needs and information
processing abilities of consumers. Often they do not present the information in a visible and
legible manner. Furthermore, the statement can be considered vague and not appropriate for
consumers to assess the risk accurately. Small improvements of the label can be devised.
However, scientific uncertainty surrounding food allergies hinders a detailed prescription of
the risk on the food label. Notwithstanding the shortcomings of “may contain” statements
in general, courts will be reluctant to accept liability on the basis of an inadequate warning,
since it is difficult to provide an improved alternative.
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